14 withdrawn. 14 Phase 2, 3 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 14 | Withdrawn 14 |
| Phase 1 | 3 | Withdrawn 3 |
| Phase 3 | 2 | Withdrawn 2 |
Follow Hypoglycemia: new trials by email Literature Review of Hypoglycemia trials Research Report on Hypoglycemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of the Safety and Efficacy of Pancreatic Endocrine Cell Clusters Implanted Into the Omentum of Type 1 Diabetes Patients With Severe Hypoglycemia Allogeneic Pancreatic Endocrine Cell Clusters - Diabetes Mellitus Type 1 | Phase 1 / Phase 2 | Withdrawn | Seraxis | 2025-04-01 | 2025-10-16 | |
| Diabetes Islet Preservation Immune Treatment Anti-Thymocyte Globulin (ATG), Interleukin 2, Exenatide - Diabetes Mellitus, Type 1, Hypoglycemia | Phase 1 / Phase 2 | Withdrawn | Camillo Ricordi and Jay Skyler | 2024-06-01 | 2026-01-15 | |
| Efficacy and Safety of Dasiglucagon for Treatment of Post-bariatric Hypoglycemia in Roux-en-Y Gastric Bypass (RYGB) Operated Adults Dasiglucagon, Placebo - Hypoglycemia, Glucose Metabolism Disorders | Phase 2 | Withdrawn | Zealand Pharma | 2023-02-01 | 2023-02-21 | |
| Vitamin E Efficacy in HI/HA Vitamin E - Hyperinsulinism-Hyperammonemia Syndrome | Phase 2 | Withdrawn | Children's Hospital of Philadelphia | 2022-11-01 | 2022-12-13 | |
| Safety, Tolerability, and Efficacy of Immunomodulation With AT-1501 in Combination With Transplanted Islet Cells in Adults With Brittle T1D AT-1501 IV Infusion, Isolated cadaveric islet cells - Brittle Type 1 Diabetes Mellitus | Phase 1 / Phase 2 | Withdrawn | Eledon Pharmaceuticals | 2022-09-30 | 2023-01-18 | |
| Empagliflozin and Anakinra for the Treatment of Postprandial Hypoglycemia in Patients With Prediabetes empagliflozin, anakinra, saline subcutaneous (s.c.) (placebo) - Postprandial Hypoglycemia | Phase 2 | Withdrawn | University Hospital, Basel, Switzerland | 2022-06-24 | 2026-02-20 | |
| Safety, Tolerability and Efficacy of Immunomodulation With AT-1501 in Islet Cell Transplantation AT-1501 - Type 1 Diabetes Mellitus | Phase 2 | Withdrawn | Anelixis Therapeutics, LLC | 2021-02-19 | 2022-08-10 | |
| Closed-loop Control of Glucose Levels (Artificial Pancreas) for 5 Days in Adults With Type 1 Diabetes 5-day intervention with single-hormone closed-loop strategy, 5-day intervention with sensor-augmented pump therapy, Insulin pump - Type 1 Diabetes | Phase 2 | Withdrawn | Institut de Recherches Cliniques de Montreal | 2018-03-01 | 2018-01-31 | |
| Closed-loop Control of Postprandial Glucose Levels in Children and Adults With Type 1 Diabetes 6-day intervention with sensor-augmented pump therapy, 6-day intervention with single-hormone closed-loop strategy, 6-day intervention with dual-hormone closed-loop strategy - Type 1 Diabetes | Phase 2 | Withdrawn | Institut de Recherches Cliniques de Montreal | 2018-01-01 | 2017-10-27 | |
| Pasireotide in Hyperinsulinemic Hypoglycemia Pasireotide 0.6Mg Solution for Injection, Saline Solution - Congenital Hyperinsulinism, Insulinoma | Phase 2 | Withdrawn | Montefiore Medical Center | 2017-04-01 | 2021-05-14 | |
| Efficacy of Small Subcutaneous Glucagon Dose to Treat Hypoglycemia in Adults With Type 1 Diabetes Hypoglycaemic hyperinsulinemic clamp, Glucagon - Type 1 Diabetes | Phase 2 | Withdrawn | Institut de Recherches Cliniques de Montreal | 2013-04-01 | 2013-12-04 | |
| Effects of Pulsatile Intravenous Insulin Delivery on Hypoglycemic Unawareness Pulsatile Intravenous Insulin Therapy (Humulin R, Novolog) - Hypoglycemia | Phase 2 / Phase 3 | Withdrawn | Florida Atlantic University | 2007-01-01 | 2016-08-10 | |
| Effects of Pulsatile Intravenous Insulin Delivery on Diabetic Neuropathy in pATIENTS (Pts) With Type 1 and Type 2 Diabetes Placebo, Pulsatile IV insulin delivery (humalog, humulin, novolog) - Diabetic Neuropathy | Phase 2 / Phase 3 | Withdrawn | Florida Atlantic University | 2005-02-01 | 2016-08-10 | |
| Closed-loop Control of Glucose Levels (Artificial Pancreas) for 15 Weeks in Adolescents and Adults With Type 1 Diabetes 15-week intervention with sensor-augmented pump, 15-week intervention with single-hormone closed-loop, 15-week intervention with dual-hormone closed-loop - Type 1 Diabetes | Phase 2 | Withdrawn | Institut de Recherches Cliniques de Montreal | 2019-07-23 |
Diabetes Mellitus, Type 1 (8) · Autoimmune Diseases (3) · Diabetes Mellitus (3) · Endocrine System Diseases (3) · Insulin Resistance (3) · Diabetes Complications (2) · Glucose Metabolism Disorders (2) · Hyperglycemia (2) · Hyperinsulinism (2) · Immune System Diseases (2) · Metabolic Diseases (2) · Congenital Hyperinsulinism (1) · Diabetes Mellitus, Insulin-Dependent, 2 (1) · Diabetic Neuropathies (1)
Nutritional and Metabolic Diseases (14) · Glucose Metabolism Disorders (12) · Metabolic Diseases (12) · Endocrine System Diseases (9) · Diabetes Mellitus (8) · Immune System Diseases (6) · Autoimmune Diseases (5) · Hyperinsulinism (3) · Adenoma (1) · Adenoma, Islet Cell (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Endocrine Gland Neoplasms (1)
Insulin (4) · Glucagon (3) · Methods (3) · Continuous Glucose Monitoring (2) · Insulin Aspart (2) · Insulin Infusion Systems (2) · Adalimumab (1) · Antilymphocyte Serum (1) · Exenatide (1) · Injections (1) · Insulin Lispro (1) · Insulin, Regular, Human (1) · Interleukin 1 Receptor Antagonist Protein (1) · Interleukin-2 (1) · Saline Solution (1)
Institut de Recherches Cliniques de Montreal (4) · Florida Atlantic University (2) · Anelixis Therapeutics, LLC (1) · Camillo Ricordi and Jay Skyler (1) · Children's Hospital of Philadelphia (1) · Eledon Pharmaceuticals (1) · Montefiore Medical Center (1) · Seraxis (1) · University Hospital, Basel, Switzerland (1) · Zealand Pharma (1)
United States (5) · Canada (4)
Betty Tuller, PhD (2) · Jeff Bornstein, MD (2) · Elizabeth A Rosenfeld, MD (1) · Erika Brutsaert, M.D., M.P.H. (1) · Marc Y. Donath, Prof. Dr. med. (1) · Rodolfo Alejandro, M.D. (1)